purine has been researched along with Melanoma in 2 studies
1H-purine : The 1H-tautomer of purine.
3H-purine : The 3H-tautomer of purine.
9H-purine : The 9H-tautomer of purine.
7H-purine : The 7H-tautomer of purine.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Reports have shown an increased risk of melanoma skin cancer (MSC) with exposure to tumor necrosis factor alpha (TNF-α) inhibitors and non-melanoma skin cancer (NMSC) with thiopurine exposure in inflammatory bowel disease (IBD) patients." | 7.80 | Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System. ( Deepak, P; McKenna, MR; Stobaugh, DJ, 2014) |
| "Reports have shown an increased risk of melanoma skin cancer (MSC) with exposure to tumor necrosis factor alpha (TNF-α) inhibitors and non-melanoma skin cancer (NMSC) with thiopurine exposure in inflammatory bowel disease (IBD) patients." | 3.80 | Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System. ( Deepak, P; McKenna, MR; Stobaugh, DJ, 2014) |
| "Melanoma is the most aggressive type of skin cancer, leading to metabolic rewiring and enhancement of metastatic transformation." | 1.56 | Human Melanoma-Cell Metabolic Profiling: Identification of Novel Biomarkers Indicating Metastasis. ( Benaki, D; Giannopoulou, AF; Gikas, E; Iliou, A; Konstantakou, EG; Kosmopoulou, M; Mikros, E; Panagiotakis, A; Papassideri, IS; Stravopodis, DJ; Velentzas, AD, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kosmopoulou, M | 1 |
| Giannopoulou, AF | 1 |
| Iliou, A | 1 |
| Benaki, D | 1 |
| Panagiotakis, A | 1 |
| Velentzas, AD | 1 |
| Konstantakou, EG | 1 |
| Papassideri, IS | 1 |
| Mikros, E | 1 |
| Stravopodis, DJ | 1 |
| Gikas, E | 1 |
| McKenna, MR | 1 |
| Stobaugh, DJ | 1 |
| Deepak, P | 1 |
2 other studies available for purine and Melanoma
| Article | Year |
|---|---|
Human Melanoma-Cell Metabolic Profiling: Identification of Novel Biomarkers Indicating Metastasis.
Topics: Biomarkers; Cell Line, Tumor; Chromatography, Liquid; Discriminant Analysis; Female; Humans; Least-S | 2020 |
Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents; Databases, Fac | 2014 |